Memantine Eg

Memantine, the active ingredient in Memantine EG, is a non‑competitive NMDA receptor antagonist presented as an oral formulation for oral administration. It is used to treat cognitive decline associated with Alzheimer’s disease in adult patients, helping to reduce excitotoxic neuronal damage and modestly improve functional outcomes.

GNH USA supplies Memantine EG as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU manufacturing standards and providing reliable global distribution. The company ensures quality control, traceability and regulatory compliance across all shipments.

Memantine acts as an NMDA receptor antagonist and is employed in the management of Alzheimer’s disease.

Alzheimer’s disease (moderate to severe): improves cognition and functional abilities in affected patients. Alzheimer’s disease (mild to moderate): may provide modest benefit in slowing symptom progression. Behavioral symptoms of Alzheimer’s disease: can help reduce agitation and improve daily functioning.

Memantine may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Fatigue - Hypertension

Serious or Rare Side Effects: - Seizures - Cardiac arrhythmia - Hepatic injury - Stevens‑Johnson syndrome or other severe skin reactions - Hypersensitivity (including anaphylaxis) - Suicidal thoughts or behavior

When prescribing memantine, clinicians should consider several safety factors. - Renal impairment: dose adjustment may be required and renal function should be monitored. - Hepatic impairment: use with caution; monitor liver enzymes. - History of seizures: monitor for increased seizure frequency. - Concomitant use with other NMDA antagonists: avoid additive CNS effects. - Pregnancy and lactation: safety not established; weigh risks and benefits. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Memantine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity and confusion. - Ketamine: additive NMDA antagonism may cause excessive CNS depression. - Strong CYP450 inhibitors (e.g., quinidine): may raise memantine plasma levels.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may reduce therapeutic benefit. - Diuretics: may affect electrolyte balance and increase dizziness. - Antihypertensive drugs: may enhance blood‑pressure‑lowering effect.